Repligen Co. (NASDAQ:RGEN) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 2,420,000 shares, a decline of 29.4% from the December 31st total of 3,430,000 shares. Based on an average daily trading volume, of 393,500 shares, the short-interest ratio is presently 6.1 days. Currently, 5.1% of the company’s shares are sold short.

Hedge funds and other institutional investors have recently modified their holdings of the stock. California Public Employees Retirement System boosted its holdings in shares of Repligen by 64.4% in the fourth quarter. California Public Employees Retirement System now owns 186,894 shares of the biotechnology company’s stock valued at $17,288,000 after buying an additional 73,221 shares during the period. Dupont Capital Management Corp boosted its holdings in shares of Repligen by 67.2% in the fourth quarter. Dupont Capital Management Corp now owns 8,528 shares of the biotechnology company’s stock valued at $789,000 after buying an additional 3,428 shares during the period. Yorktown Management & Research Co Inc boosted its holdings in shares of Repligen by 4.2% in the fourth quarter. Yorktown Management & Research Co Inc now owns 7,900 shares of the biotechnology company’s stock valued at $731,000 after buying an additional 320 shares during the period. New York State Teachers Retirement System boosted its holdings in shares of Repligen by 0.5% in the fourth quarter. New York State Teachers Retirement System now owns 41,617 shares of the biotechnology company’s stock valued at $3,850,000 after buying an additional 217 shares during the period. Finally, State of Michigan Retirement System boosted its holdings in shares of Repligen by 2.2% in the fourth quarter. State of Michigan Retirement System now owns 13,800 shares of the biotechnology company’s stock valued at $1,277,000 after buying an additional 300 shares during the period. Hedge funds and other institutional investors own 84.72% of the company’s stock.

A number of research firms recently weighed in on RGEN. Svb Leerink reissued an “outperform” rating and set a $100.00 price target on shares of Repligen in a research note on Tuesday, October 15th. First Analysis raised shares of Repligen from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $107.00 to $110.00 in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Repligen in a research note on Monday, January 13th. ValuEngine downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Leerink Swann started coverage on shares of Repligen in a research note on Tuesday, October 15th. They set an “outperform” rating and a $100.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Repligen currently has an average rating of “Buy” and an average price target of $105.63.

NASDAQ RGEN traded up $2.16 during trading on Tuesday, reaching $101.78. 9,895 shares of the stock traded hands, compared to its average volume of 278,462. The firm has a market cap of $5.24 billion, a price-to-earnings ratio of 208.14, a price-to-earnings-growth ratio of 4.53 and a beta of 1.12. The stock’s 50-day moving average price is $94.75 and its 200 day moving average price is $87.65. The company has a quick ratio of 14.70, a current ratio of 16.03 and a debt-to-equity ratio of 0.25. Repligen has a fifty-two week low of $52.87 and a fifty-two week high of $102.76.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.07. The firm had revenue of $69.45 million during the quarter, compared to analysts’ expectations of $66.10 million. Repligen had a net margin of 9.28% and a return on equity of 6.50%. The business’s revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.20 earnings per share. Analysts anticipate that Repligen will post 1.03 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Story: What is the market perform rating?

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.